Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim has submitted a clinical trials application (CTA) to the European regulatory authorities for a Phase I trial with a Nanobody for the treatment of Alzheimer's disease.
Subscribe to our email newsletter
In January 2007, Boehringer and Ablynx entered into research and licensing agreement to discover new therapies for Alzheimer’s disease.
The nanobody, developed under the collaboration, triggered a €1m milestone payment to Ablynx.
Ablynx CEO and chairman Edwin Moses said, "This development candidate has the potential to be a first-in- class therapy for Alzheimer’s disease and demonstrates the power of our Nanobody platform."
The areement has a potential value of $265m in upfront and milestone payments plus undisclosed royalties on product sales.